NZ750221A - Anti-pd-1 antibodies, method for producing same and method for using same - Google Patents

Anti-pd-1 antibodies, method for producing same and method for using same

Info

Publication number
NZ750221A
NZ750221A NZ750221A NZ75022117A NZ750221A NZ 750221 A NZ750221 A NZ 750221A NZ 750221 A NZ750221 A NZ 750221A NZ 75022117 A NZ75022117 A NZ 75022117A NZ 750221 A NZ750221 A NZ 750221A
Authority
NZ
New Zealand
Prior art keywords
antibodies
same
oncology
producing
human
Prior art date
Application number
NZ750221A
Other languages
English (en)
Inventor
Olga Vladimirovna Goncharova
Viktoriia Mikhailovna Ekimova
Dmitry Valeryevich Korzhavin
Yulia Sergeevna Chernykh
Timofey Aleksandrovich Nemankin
Valery Vladimirovich Solovyev
Anna Konstantinovna Vladimirova
Irina Andreevna Bulankina
Sergei Vasilyevich Diduk
Anna Vladimirovna Eroshova
Iakov Iurevich Ustiugov
Marina Vladimirovna Artiukhova
Andrei Borisovich Ulitin
Roman Alekseevich Ivanov
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of NZ750221A publication Critical patent/NZ750221A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ750221A 2016-07-13 2017-07-04 Anti-pd-1 antibodies, method for producing same and method for using same NZ750221A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения
PCT/RU2017/050056 WO2018013017A1 (ru) 2016-07-13 2017-07-04 Анти-pd-1-антитела, способ их получения и способ применения

Publications (1)

Publication Number Publication Date
NZ750221A true NZ750221A (en) 2022-09-30

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ750221A NZ750221A (en) 2016-07-13 2017-07-04 Anti-pd-1 antibodies, method for producing same and method for using same

Country Status (21)

Country Link
US (1) US11136408B2 (enExample)
EP (1) EP3486257A4 (enExample)
JP (1) JP6993992B2 (enExample)
KR (1) KR102482710B1 (enExample)
CN (1) CN110023335B (enExample)
BR (1) BR112019000436A2 (enExample)
CA (1) CA3021372A1 (enExample)
CL (1) CL2018003407A1 (enExample)
CO (1) CO2019001246A2 (enExample)
CR (1) CR20190009A (enExample)
EC (1) ECSP19010852A (enExample)
JO (1) JOP20190002A1 (enExample)
MA (1) MA44547B1 (enExample)
MX (1) MX2018014937A (enExample)
NI (1) NI201900002A (enExample)
NZ (1) NZ750221A (enExample)
PE (1) PE20190450A1 (enExample)
PH (1) PH12018550179A1 (enExample)
RU (1) RU2656181C1 (enExample)
WO (1) WO2018013017A1 (enExample)
ZA (1) ZA201900792B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
JP7275030B2 (ja) 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体およびその使用
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
US10995149B2 (en) 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
EP3823991A4 (en) * 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
JP7680967B2 (ja) * 2019-06-14 2025-05-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｐｄ－１に対する抗体およびその使用方法
TWI844666B (zh) 2019-08-22 2024-06-11 俄羅斯聯邦商拜奧卡德聯合股份公司 抗ＰＤ－１抗體Ｐｒｏｌｇｏｌｉｍａｂ的水性藥物組合物及其用途
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
US20250270320A1 (en) * 2020-12-10 2025-08-28 Eutilex Co., Ltd. Anti-pd-1 antibody and uses thereof
PE20241732A1 (es) 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos
MA62924A1 (fr) 2021-04-08 2024-03-29 Biocad Joint Stock Co Traitement de néoplasies malignes à l'aide d'une combinaison d'anticorps anti-pd-1
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN116925223A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pd-1单克隆抗体及其衍生物和用途
EP4598960A1 (en) * 2022-10-05 2025-08-13 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
EP3279215B1 (en) * 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CN102892786B (zh) * 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
LT2691417T (lt) * 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
RS61400B1 (sr) * 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
SMT202300039T1 (it) * 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
ZA201900792B (en) 2020-03-25
NI201900002A (es) 2019-06-11
KR102482710B1 (ko) 2023-01-02
EP3486257A1 (en) 2019-05-22
JOP20190002A1 (ar) 2019-01-10
EP3486257A4 (en) 2020-03-04
PE20190450A1 (es) 2019-03-29
US11136408B2 (en) 2021-10-05
AU2017297138A2 (en) 2019-02-21
JP2019527543A (ja) 2019-10-03
CL2018003407A1 (es) 2019-03-29
JP6993992B2 (ja) 2022-01-14
WO2018013017A1 (ru) 2018-01-18
MA44547B1 (fr) 2021-09-30
AU2017297138A8 (en) 2019-02-28
CN110023335B (zh) 2024-05-17
AU2017297138A1 (en) 2019-02-14
CO2019001246A2 (es) 2019-02-19
CR20190009A (es) 2019-06-05
US20190127478A1 (en) 2019-05-02
RU2656181C1 (ru) 2018-05-31
MX2018014937A (es) 2019-05-16
PH12018550179A1 (en) 2019-03-11
MA44547A1 (fr) 2020-01-31
ECSP19010852A (es) 2019-06-30
BR112019000436A2 (pt) 2019-10-01
CA3021372A1 (en) 2018-01-18
KR20190029641A (ko) 2019-03-20
CN110023335A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG10201900571YA (en) Anti-pd-1 antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EP4631978A3 (en) Humanized or chimeric cd3 antibodies
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12019502298A1 (en) Monoclonal antibody to pd-l1
ZA202008095B (en) Humanized antibodies against psma
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
MY210018A (en) Monoclonal antibody that binds specifically to gitr
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
TH1901000154A (th) แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว
BR112016022013A2 (pt) anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15) e usos dos mesmos para tratamento de caquexia do câncer e câncer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUL 2024 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20230608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUL 2025 BY WRAYS PTY LTD

Effective date: 20240514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 JUL 2026 BY ARCEO IP

Effective date: 20250701